Foliglurax, a positive allosteric modulator of the metabotrophic glutamate receptor 4, protects dopaminergic neurons in MPTP-lesioned male mice
Brain Research · 2023
DOI: 10.1016/j.brainres.2023.148349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2023. Verfasst von Mélanie Bourque und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du CHU de Québec, Axe Neurosciences, Québec, QC G1V4G2, Canada. Hauptthemen laut MEDLINE: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Antiparkinson Agents, Dopaminergic Neurons, Neuroprotective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: H. Lundbeck A/S.
Abstract (Originalsprache)
Overactivity of the corticostriatal glutamatergic pathway is documented in Parkinson's disease (PD) and stimulation of presynaptic metabotropic glutamate (mGlu) receptors 4 on these striatal afferents inhibits glutamate release normalizing neuronal activity in the basal ganglia. Moreover, mGlu4 receptors are also expressed in glial cells and are able to modulate glial function making this receptor a potential target for neuroprotection. Hence, we investigated whether foliglurax, a positive allosteric modulator of mGlu4 receptors with high brain exposure after oral administration, has neuroprotective effects in MPTP mice to model early PD. Male mice were treated daily from day 1 to 10 with 1, 3 or 10 mg/kg of foliglurax and administered MPTP on the 5th day then euthanized on the 11th day. Dopamine neuron integrity was assessed with measures of striatal dopamine and its metabolites levels, striatal and nigral dopamine transporter (DAT) binding and inflammation with markers of striatal astrocytes (GFAP) and microglia (Iba1). MPTP lesion produced a decrease in dopamine, its metabolites and striatal DAT specific binding that was prevented by treatment with 3 mg/kg of foliglurax, whereas 1 and 10 mg/kg had no beneficial effect. MPTP mice had increased levels of GFAP; foliglurax treatment (3 mg/kg) prevented this increase. Iba1 levels were unchanged in MPTP mice compared to control mice. There was a negative correlation between dopamine content and GFAP levels. Our results show that positive allosteric modulation of mGlu4 receptors with foliglurax provided neuroprotective effects in the MPTP mouse model of PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche du CHU de Québec, Axe Neurosciences, Québec, QC G1V4G2, Canada.
- H. Lundbeck A/S, 2500 Valby, Denmark.
- Centre de Recherche du CHU de Québec, Axe Neurosciences, Québec, QC G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, Université Laval, Québec, QC G1V 0A6, Canada. Electronic address: therese.dipaolo@crch…
Förderung
- H. Lundbeck A/S
Zitieren
APA
Bourque, M., Morissette, M., Conquet, F., Charvin, D., & Di Paolo, T. (2023). Foliglurax, a positive allosteric modulator of the metabotrophic glutamate receptor 4, protects dopaminergic neurons in MPTP-lesioned male mice. Brain Research. https://doi.org/10.1016/j.brainres.2023.148349
Vancouver
Bourque M, Morissette M, Conquet F, Charvin D, Di Paolo T. Foliglurax, a positive allosteric modulator of the metabotrophic glutamate receptor 4, protects dopaminergic neurons in MPTP-lesioned male mice. Brain Research. 2023. doi:10.1016/j.brainres.2023.148349
BibTeX
@article{Bourque2023,
author = {Bourque, Mélanie and Morissette, Marc and Conquet, François and Charvin, Delphine and Di Paolo, Thérèse},
title = {Foliglurax, a positive allosteric modulator of the metabotrophic glutamate receptor 4, protects dopaminergic neurons in MPTP-lesioned male mice},
journal = {Brain Research},
year = {2023},
doi = {10.1016/j.brainres.2023.148349}
}
EUVIMED